- Trial phase
- Not stated
- Time to market
- unknown, no clinical trial, FDA, or company disclosure record for DYNE-302 could be verified this session; absence from ingested ClinicalTrials.gov/FDA data suggests it is at most an early/preclinical-stage program, but this cannot be confirmed.
- Why 2/10
- No hard, dated catalyst for DYNE-302 exists in the next ~12 months, no trial, FDA, or press records for the drug were found in any source this session, and Dyne's actual binary catalysts (z-rostudirsen PDUFA Jan 21, 2027; z-basivarsen ACHIEVE topline Q1 2027) belong to other programs, so DYNE-302 is at most a minor, unverifiable early-stage program.
Near-term DYN moves will be driven by z-rostudirsen's PDUFA (Jan 21, 2027) and z-basivarsen's Q1 2027 topline, not by this program.
Price Chart
Executive Summary
DYNE-302 is a drug code attributed to Dyne Therapeutics (Nasdaq: DYN), a clinical-stage neuromuscular biotech confirmed via SEC-derived records. Dyne's stock value is instead carried by z-rostudirsen (DMD exon 51; BLA accepted with Priority Review, PDUFA Jan 21, 2027) and z-basivarsen (DM1; ACHIEVE topline expected Q1 2027). With no evidence of a scheduled catalyst, clinical data, or even confirmed public disclosure for DYNE-302, the drug rates neutral with minimal standalone impact on DYN.
How It Works
Not verifiable from any source retrieved this session. By context, Dyne Therapeutics builds therapies that target disease-causing genes' RNA in muscle cells using antisense oligonucleotide technology, its confirmed programs z-rostudirsen (DYNE-251, DMD exon-51 skipping) and z-basivarsen (DYNE-101, DM1) work this way, so DYNE-302 is presumed to be a similar antisense-based candidate in Dyne's neuromuscular pipeline, but its specific target and mechanism are unconfirmed.
Trial Status
No trial records found. SecBot's ingested ClinicalTrials.gov data (ticker DYN, drug "DYNE") and FDA catalyst/trial data contain zero entries for DYNE-302; the only DYNE-matched trial record is an unrelated Colgate dental study (NCT06244290). DYNE-302 does not appear in any of Dyne's press releases or SEC filings indexed locally either.
The Two-Sided Case
Upcoming Catalysts
- z-rostudirsen (DYNE-251) PDUFA target action date, Jan 21, 2027 (Priority Review BLA, DMD exon 51)
- z-basivarsen (DYNE-101) ACHIEVE registrational topline data, expected Q1 2027 (DM1)
- Any future Dyne pipeline/R&D update or disclosure that could confirm DYNE-302's target, phase, and IND timeline
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Dyne Therapeutics, Inc. PRESS-RELEASE DYN ·Originating report